Hydrogen sulfide as a therapeutic option for the treatment of Duchenne muscular dystrophy and other muscle-related diseases

2022
journal article
review article
5
cris.lastimport.scopus2024-04-24T06:06:08Z
cris.lastimport.wos2024-04-10T02:21:03Z
dc.abstract.enHydrogen sulfide ($H_{2}S$) has been known for years as a poisoning gas and until recently evoked mostly negative associations. However, the discovery of its gasotransmitter functions suggested its contribution to various physiological and pathological processes. Although $H_{2}S$ has been found to exert cytoprotective effects through modulation of antioxidant, anti-inflammatory, anti-apoptotic, and pro-angiogenic responses in a variety of conditions, its role in the pathophysiology of skeletal muscles has not been broadly elucidated so far. The classical example of muscle-related disorders is Duchenne muscular dystrophy (DMD), the most common and severe type of muscular dystrophy. Mutations in the DMD gene that encodes dystrophin, a cytoskeletal protein that protects muscle fibers from contraction-induced damage, lead to prominent dysfunctions in the structure and functions of the skeletal muscle. However, the main cause of death is associated with cardiorespiratory failure, and DMD remains an incurable disease. Taking into account a wide range of physiological functions of $H_{2}S$ and recent literature data on its possible protective role in DMD, we focused on the description of the ‘old’ and ‘new’ functions of $H_{2}S$, especially in muscle pathophysiology. Although the number of studies showing its essential regulatory action in dystrophic muscles is still limited, we propose that $H_{2}S$-based therapy has the potential to attenuate the progression of DMD and other muscle-related disorders.pl
dc.affiliationWydział Biochemii, Biofizyki i Biotechnologii : Zakład Biotechnologii Medycznejpl
dc.affiliationSzkoła Doktorska Nauk Ścisłych i Przyrodniczychpl
dc.contributor.authorKaziród, Katarzyna - 262472 pl
dc.contributor.authorMyszka, Małgorzata - 260835 pl
dc.contributor.authorDulak, Józef - 127818 pl
dc.contributor.authorŁoboda, Agnieszka - 130081 pl
dc.date.accessioned2023-02-06T13:36:19Z
dc.date.available2023-02-06T13:36:19Z
dc.date.issued2022pl
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.additionalBibliogr.pl
dc.description.number12pl
dc.description.versionostateczna wersja wydawcy
dc.description.volume79pl
dc.identifier.articleid608pl
dc.identifier.doi10.1007/s00018-022-04636-0pl
dc.identifier.eissn1420-9071pl
dc.identifier.issn1420-682Xpl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/307300
dc.languageengpl
dc.language.containerengpl
dc.rightsUdzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa*
dc.rights.licenceCC-BY
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/legalcode.pl*
dc.share.typeinne
dc.subject.enDuchenne muscular dystrophypl
dc.subject.enhydrogen sulfidepl
dc.subject.eninflammationpl
dc.subject.en$H_{2}S$ donorspl
dc.subject.enskeletal musclespl
dc.subtypeReviewArticlepl
dc.titleHydrogen sulfide as a therapeutic option for the treatment of Duchenne muscular dystrophy and other muscle-related diseasespl
dc.title.journalCellular and Molecular Life Sciencespl
dc.typeJournalArticlepl
dspace.entity.typePublication

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
0
Views per month
Downloads
kazirod_myszka_dulak_loboda_hydrogen_sulfide_as_a_therapeutic_2022.pdf
50